Tivicay 50 Mg 50 mg FC tablets
PDF Leaflet Revision Date: 2 February 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV infection in adults.
Dosage (summary)
50 mg once daily for treatment-nau00efve; 50 mg twice daily for integrase inhibitor resistant.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in first trimester; potential risk of neural tube defects; not recommended for breastfeeding.
Key Drug Interactions
- Dofetilide
- Pilsicainide
- Metformin
- Rifampicin
- Antacids containing polyvalent cations
Contraindications
- Hypersensitivity to dolutegravir
- Moderate/severe hepatic impairment
- First trimester of pregnancy
Common side effects
- Nausea
- Diarrhoea
- Headache
- Rash
- Fatigue
Counselling Points
- Take with or without food
- Monitor for signs of hypersensitivity
- Discuss pregnancy planning with healthcare provider
Serious warnings
- Hypersensitivity reactions
- Immune Reconstitution Syndrome
- Liver chemistry elevations
Important Disclaimer
The Tivicay 50 Mg 50 mg FC tablets professional information leaflet below is the property of Glaxosmithkline South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
